This clinical trial is for men and women who have advanced hematologic malignancies (blood cancers) that may be treated with a blood stem cell transplant.
   
The purpose of this research study is to find out if an experimental therapy, Orca-T, can be safely given as a blood stem cell transplant to patients with blood cancers and pre-cancerous conditions and if Ora-T results in less graft vs host disease (GVHD) than standard blood stem cell transplants.
   
Orca-T is considered experimental because it has not yet been approved by the United States Food and Drug Administration (FDA).

Orca-T is engineered in the lab that leverages donor T cells to control immune responses.

Participants in this study will be randomized to receive one of two treatments. Randomization is like flipping a coin and there is a 50/50 chance of being assigned to either group. The first group will receive Orca-T and the second group will receive the standard-of-care unmanipulated allograft derived from the peripheral blood of a matched donor.
   
Total study participation will last for approximately 2 years or until the study doctor feels it is in the participant’s best interest to discontinue the study treatment.